Searchable abstracts of presentations at key conferences on calcified tissues

ba0006p088 | (1) | ICCBH2017

Normative data for lateral distal femur bone mineral density in children from 3 to 18 years of age using Lunar Prodigy absorptiometry

Fiscaletti Melissa , Rauch Frank , Foster Bethany , Alos Nathalie

Objectives: Children with compromised weight bearing and limited mobility are particularly at risk for fractures with minimal trauma. Unfortunately, they can also present several obstacles that can impede proper dual X-ray absorptiometry (DXA) scan assessment of whole body or spine bone mineral density (BMD). Since the distal femur is the most common site of fracture in those patients, the lateral distal femur (LDF) represents the site that best addresses the challenges of BMD...

ba0007p8 | (1) | ICCBH2019

Polyhydramnios: sole risk factor for non-traumatic fractures in two infants

Nadeau Genevieve , Olivier Patricia , Fiscaletti Melissa , Campeau Philippe , Alos Nathalie

Bone loading is a primary determinant of bone strength in later childhood and adulthood. Our understanding of how mechanical stimuli generated by foetal kicking and movements impact skeletal development is still limited. Many studies suggest that a sufficient and balanced supply of energy, proteins, vitamins, calcium, phosphorus, and other nutrients is an essential prerequisite for normal bone development. However, only few studies highlight the contribution of the biomechanic...

ba0007p134 | (1) | ICCBH2019

First report of skin reaction with Zoledronic Acid

Olivier Patricia , Fiscaletti Melissa , Desroches Anne , Alos Nathalie

Adverse reactions to bisphosphonates are common and thus, most of them are predictable side effects to the drug. Allergic reactions or skin reactions of any type or severity associated with bisphosphonates have been scarcely described in the literature. Allergic and skin reactions to bisphosphonates have been estimated to occur in less than 1% of patients. The mechanism of these reactions is unknown, although it is presumed to be IgE mediated. All of the bisphosphonates share ...

ba0004p148 | (1) | ICCBH2015

Prevalence of vertebral fractures in survivors of childhood acute lymphoblastic leukemia

Fiscaletti Melissa , Dubois Josee , Miron Marie-Claude , Krajinovic Maja , Laverdiere Caroline , Sinnett Daniel , Alos Nathalie

Improvements on the overall cure rates for childhood acute lymphoblastic leukemia (ALL) have allowed the cure of over 85% of treated patients. At least 70% of survivors of childhood ALL cancers have substantial morbidities as a result of their treatment. Long term musculoskeletal complications in this population are currently receiving increasing attention because of their negative impact on the quality of life and ability to perform appropriate activities. Our objective was t...

ba0007p146 | (1) | ICCBH2019

Does prior bisphosphonate therapy in children and adolescents with cerebral palsy alter surgical outcomes?

Fiscaletti Melissa , Loucos Robert , Jamil Kamal Abdul , Biggins Andrew , Munns Craig , Pacey Verity

Background: Children and adolescents with cerebral palsy (CP) experience musculoskeletal complications including spinal deformities, hip dysplasia and disuse osteoporosis. Bisphosphonates can improve bone mineral density, prevent fragility fractures. It is unclear if prior bisphosphonate use modifies post-operative complication in children with CP. Our aim was to compare surgical complications in children with CP with and without previous bisphosphonate treatment.<p class=...

ba0007p140 | (1) | ICCBH2019

Safety and effectiveness of stoss therapy in children

Fiscaletti Melissa , Tannous Paul , Wood Nicholas , Gunasekera Hasantha , Zurynski Yvonne , Biggins Andrew , Kilo Tatjana , Hayes Evan , Munns Craig

Objectives: Pediatric vitamin D (25-hydroxyvitamin D - 25OHD) deficiency can lead to nutritional rickets and extra-skeletal complications. Compliance with daily therapy can be difficult, making high dose, short-term vitamin D (stoss) therapy attractive to correct vitamin D deficiency. We compared the effectiveness and safety of standard versus stoss therapy in treating childhood 25OHD deficiency.Study design: Children aged 2–16 years with 25OHD &#60...

ba0007p141 | (1) | ICCBH2019

Hypercalcaemia and osteonecrosis of the jaw in association with denosumab use in the paediatric population

Wall Christie-Lee , Pacey Verity , Gray Kelly , McGee Richard , Fiscaletti Melissa , Poon Myra , Biggin Andrew , Munns Craig

Background: Denosumab (DMAB) is used in adults for the treatment of osteoporosis, giant cell tumour of bone, and cancer metastases. There are little data on paediatric use with clinical decision making reliant on adult data and clinical experience.Presenting problem: We have treated 33 children with DMAB: Perthes disease (n=9), avascular necrosis (n=17), osteoporosis (n=1), aneurysmal bone cyst (n=4) and giant cell tum...